Diabetes Australia has welcomed the Australian Authorities’s resolution to listing Tresiba Penfill (insulin degludec) on the Pharmaceutical Advantages Scheme (PBS) for folks residing with sort 1 diabetes, efficient 1 July 2026.
Tresiba is an ultra-long performing, once-daily basal insulin indicated for adults, adolescents and kids from the age of 1 yr who’re residing with sort 1 diabetes. The PBS itemizing will enhance affordability and entry to this necessary therapy possibility.
Diabetes Australia’s Group CEO Justine Cain mentioned the itemizing is a constructive step ahead in supporting folks with sort 1 diabetes to higher handle their situation.
“This necessary PBS itemizing will assist cut back the fee burden for folks residing with sort 1 diabetes and enhance the alternatives out there for managing the situation,” Ms Cain mentioned.
“This itemizing will help healthcare professionals to individualise basal insulin remedy primarily based on an individual’s scientific wants, preferences and life-style.”
“Individualised care is crucial for reaching optimum outcomes and enhancing high quality of life for folks residing with diabetes.”
Diabetes Australia emphasised that entry to reasonably priced medicines stays a key precedence, significantly for folks requiring lifelong insulin remedy.
“Managing sort 1 diabetes is complicated and calls for fixed consideration. Guaranteeing equitable entry to a variety of efficient remedies helps folks reside nicely with diabetes,” Ms Cain mentioned.
Additional data on the itemizing can be out there on the PBS web site from 1 July 2026 at www.pbs.gov.au.
